Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B.

Bzowej N, Han S, Degertekin B, Keeffe EB, Emre S, Brown R, Reddy R, Lok AS; National Institutes of Health Hepatitis B Virus Orthotopic Liver Transplantation Study Group.

Liver Transpl. 2009 Sep;15(9):1010-20. doi: 10.1002/lt.21759.

2.

Racial disparities in liver transplantation for hepatitis B: to be or not to be.

Howell CD.

Liver Transpl. 2009 Sep;15(9):1007-9. doi: 10.1002/lt.21848. No abstract available.

3.

Prognosis in liver transplantation recipients after hepatitis B virus recurrence.

Sun LY, Zhu ZJ, Qu W, Sun XY, Rao W, Liu Y.

Hepatogastroenterology. 2014 Oct;61(135):2047-51.

PMID:
25713909
4.

Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.

Al-Hamoudi W, Elsiesy H, Bendahmash A, Al-Masri N, Ali S, Allam N, Al Sofayan M, Al Bahili H, Al Sebayel M, Broering D, Saab S, Abaalkhail F.

World J Gastroenterol. 2015 Jul 14;21(26):8140-7. doi: 10.3748/wjg.v21.i26.8140.

5.

Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma.

Wong SN, Reddy KR, Keeffe EB, Han SH, Gaglio PJ, Perrillo RP, Tran TT, Pruett TL, Lok AS.

Liver Transpl. 2007 Mar;13(3):334-42.

6.

Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.

Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D.

Gastroenterology. 2008 Jun;134(7):1890-9; quiz 2155. doi: 10.1053/j.gastro.2008.02.064. Epub 2008 Mar 4.

PMID:
18424269
7.

Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes.

Gaglio P, Singh S, Degertekin B, Ishitani M, Hussain M, Perrillo R, Lok AS; National Institutes of Health Hepatitis B Virus-Orthotopic Liver Transplantation Study Group.

Liver Transpl. 2008 Oct;14(10):1420-7. doi: 10.1002/lt.21563.

8.

Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.

Chung GE, Kim W, Lee JH, Kim YJ, Yoon JH, Lee JM, Lee JY, Kim SH, Kim D, Lee HS.

J Gastroenterol Hepatol. 2011 Nov;26(11):1638-45. doi: 10.1111/j.1440-1746.2011.06777.x.

PMID:
22011297
9.

Recurrence of hepatitis C virus (genotype 4) infection after living-donor liver transplant in Egyptian patients.

Yosry A, Abdel-Rahman M, Esmat G, El-Serafy M, Omar A, Doss W, Zayed N, Said M, Ismail T, Hosny A, Marawan E, El-Malt O, Kamel RR, Hatata Y, El-Taweel A, Ghali A, Sabri H, Kamel S, El-Gabaly H.

Exp Clin Transplant. 2009 Sep;7(3):157-63.

10.

The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.

Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM; ESLD-HIV Working Group Investigators.

Liver Transpl. 2009 Sep;15(9):1133-41. doi: 10.1002/lt.21735.

11.
12.

HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience.

Yuan CH, Xiu DR, Jiang B, Li ZF, Li L, Song SB, Zhang TL.

Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):149-53.

14.

Liver transplantation in patients with hepatitis B virus infection: outcome in Asian versus white patients.

Teo EK, Han SH, Terrault N, Luketic V, Jensen D, Keeffe EB, Lok AS; HBV-OLT Study Group.

Hepatology. 2001 Jul;34(1):126-32.

PMID:
11431743
15.

Hepatitis B prophylaxis using lamivudine and individualized low-dose hepatitis B immunoglobulin in living donor liver transplantation.

Jiang L, Yan L, Wen T, Li B, Zhao J, Yang J, Xu M, Wang W.

Transplant Proc. 2013 Jul-Aug;45(6):2326-30. doi: 10.1016/j.transproceed.2013.03.028.

PMID:
23953544
16.
17.

Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study.

Han SH, Reddy KR, Keeffe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekin B, Lok A; NIH HBV OLT Study Group.

Clin Transplant. 2011 Mar-Apr;25(2):E152-62. doi: 10.1111/j.1399-0012.2010.01349.x. Epub 2010 Nov 16.

18.

Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.

Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM.

Gastroenterology. 2011 Oct;141(4):1212-9. doi: 10.1053/j.gastro.2011.06.083. Epub 2011 Jul 14.

PMID:
21762659
19.

Comparison of hepatitis B prophylactic outcomes in living donor liver transplantation recipients who meet the Milan or UCSF criteria.

Jiang L, Yan LN, Wen TF, Li B, Yang JY.

Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):494-9.

20.

High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence.

Li MR, Chen GH, Cai CJ, Wang GY, Zhao H.

Digestion. 2011;84(2):134-41. doi: 10.1159/000324197. Epub 2011 Apr 18.

PMID:
21502763
Items per page

Supplemental Content

Write to the Help Desk